---
title: Hikal vs 重庆兴泰濠制药有限公司 (Sintaho)
slug_a: hikal
slug_b: sintaho
site: cdmo
review_signal_gate: closed
canonical_path: /compare/hikal/sintaho
generated_by: BioBM Editorial AI
---

# Hikal vs 重庆兴泰濠制药有限公司 (Sintaho)

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Hikal (hikal) is listed for cdmo. Hikal is a contract development and manufacturing partner for pharmaceuticals, biotech, and specialty chemicals, offering API synthesis, process development, and custom manufacturing at FDA-approved facilities across five Indian manufacturing sites.

Services: 6. Modalities: 1. Indications: 0. Locations: 6. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (6).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

重庆兴泰濠制药有限公司 (Sintaho) (sintaho) is listed for cdmo. China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.

Services: 4. Modalities: 2. Indications: 0. Locations: 1. Certifications: 1. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (4).

Review summary: Review summary withheld until site-level review gate opens.